Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression
AbstractThe androgen receptor (AR) plays important roles in prostate cancer development and prostate tumor growth. After binding to androgens, AR functions as a nuclear receptor and translocates to the nucleus to bind to specific AR-binding sites (ARBSs). AR regulates epigenetic factor recruitments to activate its downstream signaling. Although androgen deprivation therapy (ADT) is initially useful for prostate cancer patients, most patients eventually show resistance with hormone-refractory prostate cancers (HRPCs) or castration-resistant prostate cancers (CRPCs). Thus, new therapeutic strategies targeting HRPCs/CRPCs should be very important for clinical medicine as well as prostate cancer biology. Past studies have shown that mechanisms such as AR overexpression, hypersensitivity, variants and reprograming are responsible for developing HRPCs/CRPCs. These findings suggest that AR target genes will be major key factors. In this review article, we focus mainly on the androgen-regulated microRNAs (miRNAs) to summarize the contribution of miRNA-mediated pathways for prostate cancer progression. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Takayama, K.-I.; Misawa, A.; Inoue, S. Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression. Cancers 2017, 9, 102.
Takayama K-I, Misawa A, Inoue S. Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression. Cancers. 2017; 9(8):102.Chicago/Turabian Style
Takayama, Ken-ichi; Misawa, Aya; Inoue, Satoshi. 2017. "Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression." Cancers 9, no. 8: 102.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.